NASDAQ:CRSP CRISPR Therapeutics (CRSP) Stock Price, News & Analysis $47.59 -0.97 (-2.00%) Closing price 04:00 PM EasternExtended Trading$47.39 -0.20 (-0.42%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CRISPR Therapeutics Stock (NASDAQ:CRSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISPR Therapeutics alerts:Sign Up Key Stats Today's Range$46.92▼$48.3350-Day Range$44.34▼$58.7852-Week Range$35.38▼$78.48Volume1.69 million shsAverage Volume1.86 million shsMarket Capitalization$4.59 billionP/E RatioN/ADividend YieldN/APrice Target$65.47Consensus RatingModerate Buy Company Overview CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes. Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals. In addition to hematology, CRISPR Therapeutics is advancing oncology candidates such as CTX110, CTX112 and CTX120, which use engineered immune cells to target various blood cancers. The company also maintains partnerships with organizations including ViaCyte for potential treatments in type 1 diabetes, further diversifying its pipeline across therapeutic areas. Founded in 2013 and headquartered in Zug, Switzerland, CRISPR Therapeutics maintains a significant presence in the United States, with research and development facilities in Cambridge, Massachusetts. The company’s global footprint supports clinical trials across North America and Europe, reflecting its commitment to addressing unmet medical needs in key healthcare markets worldwide. Under the leadership of Chief Executive Officer Samarth Kulkarni, CRISPR Therapeutics continues to expand its manufacturing capabilities and prepare for potential regulatory filings. Co-founder Emmanuelle Charpentier, a pioneer in CRISPR science, serves on the board, guiding the company’s strategic direction as it advances a novel class of genetic medicines toward commercialization.AI Generated. May Contain Errors. Read More CRISPR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCRSP MarketRank™: CRISPR Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 304th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 1 strong buy rating, 10 buy ratings, 6 hold ratings, and 2 sell ratings.Upside PotentialCRISPR Therapeutics has a consensus price target of $65.47, representing about 37.6% upside from its current price of $47.59.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CRISPR Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.08) to ($4.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CRISPR Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.31% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 11.91, which indicates bearish sentiment.Change versus previous monthShort interest in CRISPR Therapeutics has recently decreased by 1.18%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.66 News SentimentCRISPR Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CRISPR Therapeutics this week, compared to 9 articles on an average week.Search Interest37 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 76% compared to the previous 30 days.MarketBeat Follows33 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 725% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,578,097.00 in company stock.Percentage Held by Insiders4.10% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CRISPR Therapeutics' insider trading history. Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRSP Stock News HeadlinesCRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know4 hours ago | finance.yahoo.comCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?4 hours ago | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 19 at 1:00 AM | Brownstone Research (Ad)CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data BuildMay 18 at 9:30 AM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 12, 2026 | americanbankingnews.com1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?May 11, 2026 | fool.com3 Biotech Stocks That Could Benefit from the Patent CliffBiotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets...April 27, 2026 | marketbeat.comSee More Headlines CRSP Stock Analysis - Frequently Asked Questions How have CRSP shares performed this year? CRISPR Therapeutics' stock was trading at $52.44 at the start of the year. Since then, CRSP shares have decreased by 9.2% and is now trading at $47.59. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings data on Tuesday, March, 31st. The company reported ($1.28) EPS for the quarter. The firm earned $1.46 million during the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative trailing twelve-month return on equity of 25.66%. When did CRISPR Therapeutics IPO? CRISPR Therapeutics (CRSP) raised $64 million in an IPO on Wednesday, October 19th 2016. The company issued 4,000,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are CRISPR Therapeutics' major shareholders? Top institutional shareholders of CRISPR Therapeutics include Sumitomo Mitsui Trust Group Inc. (1.92%), Amova Asset Management Americas Inc. (1.92%), Bank of America Corp DE (1.02%) and Dimensional Fund Advisors LP (0.51%). Insiders that own company stock include Simeon George, Samarth Kulkarni, James R Kasinger, Naimish Patel, Julianne Bruno, John Greene and Raju Prasad. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/31/2026Today5/19/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, CRSP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRSP CIK1674416 Webwww.crisprtx.com Phone(141) 561-3277FaxN/AEmployees460Year Founded2013Price Target and Rating Average Price Target for CRISPR Therapeutics$65.47 High Price Target$110.00 Low Price Target$9.00 Potential Upside/Downside+37.6%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($6.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$581.60 million Net Margins-13,856.54% Pretax Margin-13,774.56% Return on Equity-25.66% Return on Assets-20.39% Debt Debt-to-Equity Ratio0.32 Current Ratio17.97 Quick Ratio17.96 Sales & Book Value Annual Sales$3.51 million Price / Sales1,307.71 Cash FlowN/A Price / Cash FlowN/A Book Value$20.17 per share Price / Book2.36Miscellaneous Outstanding Shares96,450,000Free Float92,495,000Market Cap$4.59 billion OptionableOptionable Beta1.74 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CRSP) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
